Form 4: MindMed CEO Sells Shares for Tax Obligations
Insider Transaction Report
Mind Medicine (MindMed) Inc. CEO Robert Barrow sold 25,797 common shares at $9.77 each to cover tax obligations, as part of a pre-arranged 10b5-1 plan.
Summary
- Robert Barrow, CEO and Director of Mind Medicine (MindMed) Inc., sold 25,797 common shares.
- The sale occurred on September 25, 2025, at a price of $9.77 per share.
- The transaction was executed to satisfy withholding tax obligations related to the settlement of vested restricted stock units.
- This sale was conducted under a Rule 10b5-1 plan, which was adopted on June 15, 2022.
- Following this transaction, Robert Barrow beneficially owns 804,268 common shares directly.
- A Power of Attorney was granted by Robert Barrow on September 24, 2025, appointing Brandi Roberts, Mark Sullivan, Anjeanette Bowman, and John Sharrar as attorneys-in-fact for SEC filings.
Sentiment
Score: 5
Explanation: The transaction is a routine insider sale for tax purposes under a pre-arranged plan, which is generally considered neutral. It does not indicate a change in management's view of the company's prospects, nor does it introduce new positive or negative operational information.
Positives
- The transaction was executed under a pre-arranged Rule 10b5-1 plan, indicating a structured and pre-planned sale rather than an opportunistic one.
- The sale was specifically for satisfying withholding tax obligations, which is a routine and expected event for executives receiving equity compensation.
Negatives
- An insider sale, even for tax purposes, reduces the direct equity stake of a key executive in the company.
Risks
- The Power of Attorney explicitly states that it does not relieve the undersigned (Robert Barrow) from responsibility for compliance with Section 16 of the Exchange Act, including reporting requirements and potential disgorgement of profits under Section 16(b).
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
This Form 4 filing is a routine disclosure of an insider transaction and does not provide information that directly relates to broader industry trends or competitive landscape. Insider sales for tax purposes are common across all industries for executives with equity compensation.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Grant | Robert Barrow granted a Power of Attorney to Brandi Roberts, Mark Sullivan, Anjeanette Bowman, and John Sharrar to facilitate SEC filings (Forms 3, 4, 5, 144) and manage EDGAR account administration. | 2025-09-24 | Streamlines the process for Robert Barrow to comply with SEC reporting obligations by delegating administrative tasks to designated attorneys-in-fact. It clarifies responsibilities for SEC compliance but does not alter the ultimate responsibility of the insider. |
Legal Proceedings
- The filing does not mention any legal proceedings or regulatory matters.
Related Party Transactions
- The filing does not disclose any related party dealings beyond the insider transaction itself.
Stakeholder Impact
- Shareholders: A minor reduction in the CEO's direct equity ownership, but for a routine tax purpose under a pre-arranged plan, which typically has minimal impact on investor sentiment.
- Management: The Power of Attorney streamlines compliance with SEC reporting requirements for the CEO.
Next Steps
- The filing does not explicitly mention any future actions, events, or milestones beyond the reported transaction.
Key Dates
| Date | Description |
|---|---|
| 2022-06-15 | Date Rule 10b5-1 plan was adopted by Robert Barrow. |
| 2025-09-24 | Date Robert Barrow executed the Power of Attorney. |
| 2025-09-25 | Date of transaction (sale of common shares by Robert Barrow). |
| 2025-09-26 | Date the Form 4 was signed by the Attorney-in-Fact. |
Recommendation
holdThe filing details a routine insider sale by the CEO to cover tax obligations associated with vested restricted stock units, executed under a pre-arranged 10b5-1 plan. This type of transaction is not indicative of a change in the company's fundamentals or management's long-term outlook. Therefore, it does not warrant a change in investment recommendation based solely on this filing.
Keywords
Mind Medicine, MindMed, MNMD, Robert Barrow, Insider Trading, Form 4, SEC Filing, Stock Sale, CEO, Restricted Stock Units, 10b5-1 Plan, Tax Obligations, Equity Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.